Display options
Cite
Weinberg BA, Wang H, Witkiewicz AK, et al. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. J Pancreat Cancer. 2020;6(1):45-54doi: 10.1089/pancan.2020.0005.
Weinberg, B. A., Wang, H., Witkiewicz, A. K., Marshall, J. L., He, A. R., Vail, P., Knudsen, E. S., & Pishvaian, M. J. (2020). A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Journal of pancreatic cancer, 6(1), 45-54. https://doi.org/10.1089/pancan.2020.0005
Weinberg, Benjamin A, et al. "A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy." Journal of pancreatic cancer vol. 6,1 (2020): 45-54. doi: https://doi.org/10.1089/pancan.2020.0005
Weinberg BA, Wang H, Witkiewicz AK, Marshall JL, He AR, Vail P, Knudsen ES, Pishvaian MJ. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. J Pancreat Cancer. 2020 Jun 22;6(1):45-54. doi: 10.1089/pancan.2020.0005. eCollection 2020. PMID: 32642630; PMCID: PMC7337242.
Copy Download .nbib Format: NLM
Share it on

J Pancreat Cancer. 2020 Jun 22;6(1):45-54. doi: 10.1089/pancan.2020.0005. eCollection 2020.

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy.

Journal of pancreatic cancer

Benjamin A Weinberg, Hongkun Wang, Agnieszka K Witkiewicz, John L Marshall, Aiwu R He, Paris Vail, Erik S Knudsen, Michael J Pishvaian

Affiliations

  1. Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA.
  2. Roswell Park Cancer Institute, Buffalo, New York, USA.
  3. Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Johns Hopkins University School of Medicine, Washington, District of Columbia, USA.

PMID: 32642630 PMCID: PMC7337242 DOI: 10.1089/pancan.2020.0005

[No abstract available.]

© Benjamin A. Weinberg et al., 2020; Published by Mary Ann Liebert, Inc.

Keywords: CDK4/6; everolimus; mTOR; pancreatic adenocarcinoma; ribociclib

Conflict of interest statement

B.A.W. receives speaker's bureau honoraria from Lilly, Bayer, Taiho, and Sirtex, and is a consultant for Bayer. M.J.P. is speaker/consultant for AstraZeneca/MedImmune, Caris Life Sciences, Celgene, Ha

References

  1. J Clin Oncol. 2015 Apr 20;33(12):1325-33 - PubMed
  2. Hepatology. 2002 Jun;35(6):1341-50 - PubMed
  3. Hepatology. 1999 Jul;30(1):90-9 - PubMed
  4. Oncotarget. 2014 Aug 15;5(15):6512-25 - PubMed
  5. N Engl J Med. 2011 May 12;364(19):1817-25 - PubMed
  6. Clin Cancer Res. 2017 Aug 1;23(15):4055-4065 - PubMed
  7. Cell Rep. 2016 Feb 9;14(5):979-990 - PubMed
  8. Mol Clin Oncol. 2018 Apr;8(4):623-627 - PubMed
  9. J Clin Oncol. 2006 Apr 10;24(11):1770-83 - PubMed
  10. Clin Med Oncol. 2008;2:555-61 - PubMed
  11. Cancer Res. 2014 Jul 15;74(14):3947-58 - PubMed
  12. Oncogene. 2019 May;38(18):3355-3370 - PubMed
  13. N Engl J Med. 2013 Oct 31;369(18):1691-703 - PubMed
  14. Hepatology. 2003 Mar;37(3):534-43 - PubMed
  15. Cancer Res. 1997 Jan 1;57(1):169-75 - PubMed
  16. Int J Cancer. 2006 Feb 1;118(3):600-8 - PubMed
  17. Nature. 2004 Jul 8;430(6996):226-31 - PubMed
  18. Biochem Biophys Res Commun. 1993 Oct 29;196(2):1010-6 - PubMed
  19. Nat Commun. 2015 Apr 09;6:6744 - PubMed
  20. Liver. 2001 Apr;21(2):89-95 - PubMed
  21. Lancet. 2016 Feb 6;387(10018):545-557 - PubMed
  22. World J Gastroenterol. 2005 Jul 7;11(25):3850-4 - PubMed
  23. Cancer Discov. 2020 Jan;10(1):104-123 - PubMed

Publication Types

Grant support